THE SUBSTANCE LIBRARYSourced draft

ModafinilWakefulness and its limits.

A wake-promoting medicine studied in diagnosed sleep disorders. Measured wakefulness, felt alertness and everyday performance are different outcomes.

01

Overview

Modafinil is a racemic medicine used for excessive sleepiness in defined clinical settings. Human imaging links it to dopamine transporter occupancy. Sleep-disorder trials do not establish a broad cognitive benefit in healthy, rested people.

Sourced draft · editorial review pending

Clinical and mechanistic findings are shown separately. Each claim remains a sourced draft.

Assessment belongs to each claim and outcome. An article’s editorial status is not a grade of a substance’s safety or efficacy.

How it works

Dopamine transporter interaction

PET measurements support transporter occupancy and altered extracellular dopamine in the studied men. [3]

02

Subjective effects

Descriptions of experience in their reported context. Direction does not imply benefit, and these observations do not define a universal intensity score.

Reported wakefulness

Human research
Increased

Participants reported reduced sleepiness, although substantial residual sleepiness remained. [2]

Population
Patients with shift-work sleep disorder
Exposure context
200 mg before studied shifts for 3 months
03

Measured outcomes

What the research measured, for whom, and under which exposure. Findings remain attached to the study’s task or clinical endpoint.

Nighttime sleep latency

Human research
Increased

Laboratory sleep latency improved modestly relative to placebo; wakefulness did not normalize. [2]

Population
Patients with shift-work sleep disorder
Exposure context
200 mg before studied shifts for 3 months
Measure / instrument
Multiple Sleep Latency Test
Magnitude
Not quantified in this summary
04

Doses & routes

Published exposure records, distinguished by source category. These describe study or reference context and are not personal dosing recommendations.

Shift-work sleep-disorder trial

Research exposure

200 mg [2]

Ingredient / form
Modafinil · Oral study medication
Route
Oral
Frequency
Before each night-work shift
Duration
3 months
Population
209 adults with shift-work sleep disorder
Purpose
Evaluate excessive sleepiness during night work

Study exposure, not a regimen for self-directed sleep deprivation.

05

Pharmacokinetics

Absorption, metabolism and elimination depend on the analyte, route, formulation, physiology and other exposures.

Elimination half-life · Modafinil (racemate; effective repeated-dose estimate)About 15 hours [1]
OnsetNot established here [1]
PeakPlasma peak at 2–4 hours after oral administration [1]
DurationNot inferred from elimination half-life [1]

Effective half-life after repeated oral exposure; R- and S-modafinil have different kinetics. [1]

An elimination model is not established for this observation.

Measured analyte: Modafinil (racemate; effective repeated-dose estimate). Route: Oral. Formulation: Tablet. Population: Adults in prescribing-label pharmacokinetic studies.

Repeated exposure; this effective estimate does not describe both enantiomers independently.

Read the source context ↗

Sourced elimination observations

Modafinil (racemate; effective repeated-dose estimate)

15 hoursApproximate estimate [1]

Route / formulation
Oral · Tablet
Population
Adults in prescribing-label pharmacokinetic studies

Repeated exposure; this effective estimate does not describe both enantiomers independently.

Bioavailability
Absolute oral bioavailability not determined in the label [1]
Metabolism / metabolites
Hepatic metabolism; enantiomers differ in disposition [1]
06

Safety & uncertainty

Adverse effects, interactions, tolerance and withdrawal in the cited contexts. This section is not an exhaustive interaction checker.

Serious hypersensitivity

The label warns about serious rash and hypersensitivity reactions. [1]

Interactions and psychiatric effects

Prescribing information describes psychiatric reactions and interactions, including reduced effectiveness of steroidal contraceptives. [1]

Residual sleepiness

Improvement in a sleep-disorder trial did not restore normal alertness for every participant. [2]

07

Research & sources

4

The source, the finding and its limitations. Funding information is reported where curated; an unassessed disclosure does not mean a study had no commercial funding.

  1. 01
    Official prescribing label · 2026

    PROVIGIL: prescribing information

    Teva Pharmaceuticals

    Formulation-specific pharmacokinetics, warnings and interaction information.

    Limitations Formulation-specific labeling; date denotes retrieval, not original approval. It does not establish benefit outside the labeled context.

    Funding / disclosures Manufacturer prescribing information hosted by the US National Library of Medicine.

  2. 02
    Randomized placebo-controlled trial · 2005

    Modafinil for excessive sleepiness associated with shift-work sleep disorder

    Czeisler et al.
    PMID 16079371DOI 10.1056/NEJMoa041292

    Improved some sleepiness and performance measures during night work.

    Limitations Selected clinical population; residual impairment remained. A correction is linked by the publisher.

    Funding / disclosures Not assessed in this draft; consult the full article disclosures.

  3. 03
    Human PET study · 2009

    Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications

    Volkow et al.
    PMID 19293415DOI 10.1001/jama.2009.351

    Measured dopamine transporter occupancy and changes in extracellular dopamine.

    Limitations Small male-only mechanistic study; cannot establish general cognitive efficacy.

    Funding / disclosures NIH and other research support listed in the publication record.

  4. 04
    Chemical database · 2026

    Modafinil: compound identity and structure

    NCBI PubChem

    Source of the displayed formula, molecular weight, structure and connectivity SMILES.

    Limitations The parent compound identity is distinct from salts, formulations and commercial product quality.

    Funding / disclosures US National Library of Medicine.

08

Connected claims

Each relationship retains its participants, roles and context. Shared membership does not imply that substances should be combined.

transporter-occupancy

Modafinil occupied dopamine transporters in a human imaging experiment.

Healthy male participants in an acute PET experiment

Limitation Target occupancy is not a clinical outcome and the selected sample limits generalization.

Supporting sources [3]

Evidence strength: not formally assessed.

Explore the relationship graph
09

Legal context

Not assessed. Absence of a legal record is not a statement of legal status.

10

Editorial history

This article is a sourced draft. Editorial review has not been recorded. Content date: Sep 29, 2026.

View published revisionsSuggest a correction

Keep exploring

View graph
Stimulant medicine

Methylphenidate

3 shared concepts

Stimulant

Caffeine

1 shared concept

Stimulant

Nicotine

1 shared concept